Ignite Creation Date:
2025-12-24 @ 11:05 PM
Ignite Modification Date:
2025-12-31 @ 10:05 PM
Study NCT ID:
NCT05718869
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-04
First Post:
2023-01-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study
Sponsor:
City of Hope Medical Center
Organization:
Study Overview
Official Title:
A Phase 2 Study With a Safety Lead-In of the Anti-CD19 Antibody Tafasitamab With the BTK Inhibitor Zanubrutinib in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) - TaZa CLL Study
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2025-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase II trial tests how well tafasitamab and zanubrutinib works in treating patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein that signals cancer cells to multiply. This may stop the growth and spread of cancer cells. Giving tafasitamab and zanubrutinib in combination may kill more cancer cells in patients with CLL/SLL than giving either treatment alone.
Detailed Description:
PRIMARY OBJECTIVES:
I. To evaluate the safety/tolerability of tafasitamab and zanubrutinib (as assessed by unacceptable toxicity) in patients with newly diagnosed CLL. (Safety lead-in) II. To evaluate the anti-tumor activity of tafasitamab and zanubrutinib as assessed by complete response (CR) rate per International Workshop on CLL (iwCLL) 2018 criteria in patients with newly diagnosed CLL. (Phase 2)
SECONDARY OBJECTIVES:
I. To assess the toxicity of the combination of tafasitamab and zanubrutinib through evaluation of toxicities.
II. To obtain estimates of overall response rate (ORR), progression-free survival (PFS), and duration of response (DOR).
III. To assess the undetectable minimal residual disease (uMRD) rate in response to tafasitamab and zanubrutinib.
EXPLORATORY OBJECTIVES:
I. To assess the effect of tafasitamab and zanubrutinib combination on immune function of T cells and NK cells.
II. To explore mechanisms of resistance to the combination of tafasitamab and zanubrutinib.
III. To investigate the association of established biomarkers (chromosomal abnormalities, immunoglobulin heavy chain \[IGHV\] mutational status, TP53 mutational status) with response (ORR and PFS) to tafasitamab and zanubrutinib in patients with CLL.
OUTLINE: This is a dose-escalation study of zanubrutinib followed by a phase II study.
Patients receive tafasitamab intravenously (IV) and zanubrutinib orally (PO) on study. Patients also collection of blood samples on study and undergo computed tomography (CT) scan and bone marrow biopsy throughout the trial.
I. To evaluate the safety/tolerability of tafasitamab and zanubrutinib (as assessed by unacceptable toxicity) in patients with newly diagnosed CLL. (Safety lead-in) II. To evaluate the anti-tumor activity of tafasitamab and zanubrutinib as assessed by complete response (CR) rate per International Workshop on CLL (iwCLL) 2018 criteria in patients with newly diagnosed CLL. (Phase 2)
SECONDARY OBJECTIVES:
I. To assess the toxicity of the combination of tafasitamab and zanubrutinib through evaluation of toxicities.
II. To obtain estimates of overall response rate (ORR), progression-free survival (PFS), and duration of response (DOR).
III. To assess the undetectable minimal residual disease (uMRD) rate in response to tafasitamab and zanubrutinib.
EXPLORATORY OBJECTIVES:
I. To assess the effect of tafasitamab and zanubrutinib combination on immune function of T cells and NK cells.
II. To explore mechanisms of resistance to the combination of tafasitamab and zanubrutinib.
III. To investigate the association of established biomarkers (chromosomal abnormalities, immunoglobulin heavy chain \[IGHV\] mutational status, TP53 mutational status) with response (ORR and PFS) to tafasitamab and zanubrutinib in patients with CLL.
OUTLINE: This is a dose-escalation study of zanubrutinib followed by a phase II study.
Patients receive tafasitamab intravenously (IV) and zanubrutinib orally (PO) on study. Patients also collection of blood samples on study and undergo computed tomography (CT) scan and bone marrow biopsy throughout the trial.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| NCI-2022-10205 | REGISTRY | CTRP (Clinical Trial Reporting Program) | View | |
| 22183 | OTHER | City of Hope Medical Center | View | |
| P30CA033572 | NIH | None | https://reporter.nih.gov/quic… | View |